Stephen Liu: AstraZeneca Reaches Deal with Dizal to Bring Sunvozertinib to the US!
oncodaily - Stephen Liu, Director of Thoracic Oncology, Chief of the Division of Hematology and Oncology, and Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared on X: “FINALLY! AstraZeneca reaches deal with Dizal […]
AI Summary: AstraZeneca reached a deal to make sunvozertinib available in the U.S., accelerating global access for patients with EGFR exon 20 insertion–positive non–small cell lung cancer. The move follows encouraging WU-KONG1B data and signals commercial partnerships are finally translating niche trial gains into real-world treatment options for a stubbornly underserved subgroup.
Related Stories
Phase I lung cancer trials consolidating at top-performing U.S. sites / 2 months
Nine‑year CheckMate‑214 follow‑up confirms durable immunotherapy benefit / 14 days
Teclistamab shows survival benefit prompting earlier use discussions / 28 days
CAR-PRISM trial shows BCMA CAR T effective in high-risk smoldering myeloma / 2 months
Long‑term immunotherapy appears safe for alveolar soft part sarcoma / 2 months
Zongertinib emerges as first-line therapy for HER2‑mutant NSCLC / 3 months
Antoni Ribas receives AACR‑Margaret Foti Award for leadership / 3 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Neuroscience, Alzheimer's disease, Rural Health, FDA and look for the RSS link.
StackHealth Time Machine